International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Clinical trial NCT02065765 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT02065765
Sponsor: Eli Lilly and Company
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

Metastatic Gastric Cancer Metastatic Adenocarcinoma of the Gastroesophageal Junction

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.